Dr. Thomas J. Eads, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 789
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Indiana University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
IN license 01047160
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Indiana University Health Indianapolis, IN
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 789
- Services billed
- 5,060
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 1,487 | 118 |
| Pathology examination of tissue using a microscope, intermediate complexity | 1,101 | 451 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,052 | 615 |
| Destruction of precancer skin growth, 2-14 growths | 239 | 55 |
| Injection of drug or substance under skin or into muscle | 189 | 114 |
| Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 132 | 111 |
| Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | 107 | 98 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 92 | 74 |
| Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | 90 | 73 |
| Destruction of precancer skin growth, 1 growth | 82 | 73 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 6 payments worth $138 in total to this clinician.
| Galderma Laboratories, L.P. | $80.30 |
|---|---|
| AbbVie Inc. | $57.45 |
| Food and Beverage | $138 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.